Abaloparatide Before Total Knee Arthroplasty

  • End date
    Dec 19, 2023
  • participants needed
  • sponsor
    University of Wisconsin, Madison
Updated on 19 April 2022
total knee replacement
osteoporotic fracture
spinal fracture


The investigator hypothesizes that treating osteoporotic patients with abaloparatide prior to and after total knee arthroplasty will significantly reduce the amount of bone loss.


In primary unilateral total knee arthroplasty patients, The investigator will examine the effect of daily abaloparatide therapy in clinical osteoporotic patients beginning 3 months pre-op and continued for a total of 15 months. This will be compared to osteopenic patients receiving no therapy as well as previously published values in untreated osteoporotic patients 12 months following Total Knee Arthroplasty (TKA).

Condition Osteoporosis, Arthroplasties, Knee Replacement
Treatment Abaloparatide
Clinical Study IdentifierNCT04167163
SponsorUniversity of Wisconsin, Madison
Last Modified on19 April 2022


Yes No Not Sure

Inclusion Criteria

Post-menopausal women and men age ge ≥ 55 years and scheduled to undergo primary TKA at the University of Wisconsin Total Joint Program
Osteoporosis, i.e., BMD T-score (using female reference data) ≤ -2.5 at the lumbar spine, femoral neck OR total hip or ≤ -1.1 with Vertebral Fracture Assessment confirmed vertebral fracture or history of low-trauma nonvertebral fracture in the past 5 years OR osteopenia, BMD T-score (using female reference data) -1.1 to -2.4 at the lumbar spine, femoral neck or total hip and no prior low-trauma fracture
Serum calcium (albumin-corrected), serum creatinine and Parathyroid(PTH) values all within the normal range and 25(OH)D > 10 ng/mL
Willing to supplement with daily calcium and/or vitamin D3 at protocol specified doses
Able to provide written informed consent

Exclusion Criteria

Unevaluable distal femur BMD due to hardware or other artifacts
History of bone disorders (e.g., Paget's disease) other than osteoporosis
History of prior external beam or implant radiation therapy involving the skeleton other than radioiodine
History of chronic or recurrent renal, hepatic, pulmonary, allergic, cardiovascular, gastrointestinal, endocrine, central nervous system, hematologic or metabolic diseases, or immunologic, emotional and/or psychiatric disturbances that, in opinion of the principal investigator, would compromise study data validity
History of Cushing's disease, growth hormone deficiency or excess, hyperthyroidism, hypo- or hyperparathyroidism or malabsorptive syndromes within the past year
History of significantly impaired renal function (serum creatinine >2.0 mg/dL. If the serum creatinine is > 1.5 and ≤ 2.0 mg/dL, the calculated creatinine clearance (Cockcroft-Gault) must be ≥ 37 mL/min
History of nephrolithiasis or urolithiasis within the past five years
History of cancer in prior 5 years (basal cell or squamous skin cancer is permissible)
History of osteosarcoma at any time
Patients known to be positive for Hepatitis B, Hepatitis C, HIV-1 or HIV-2
Known hypersensitivity to any of the test materials or related compounds
Prior treatment with PTH- or PTHrP-derived drugs, (ABL, teriparatide or PTH (1-84))
Prior treatment with intravenous bisphosphonates at any time or oral bisphosphonates within the past three years. Patients who had received a short course of oral bisphosphonate therapy (3 months or less) may be enrolled as long as the treatment occurred 6 or more months prior to enrollment
Treatment with fluoride or strontium in the past five years or prior treatment with bone-acting investigational agents at any time
Treatment with calcitonin the past 6 months or denosumab in the past 18 months
Treatment with anticonvulsants affecting vitamin D metabolism (phenobarbital, phenytoin, carbamazepine or primidone) or chronic heparin within the prior 6 months
Treatment with anabolic steroids or calcineurin inhibitors (cyclosporin, tacrolimus)
Daily treatment with oral, intranasal or inhaled glucocorticoids in the prior 12 months
Exposure to any investigational drug within 12 months
Consumption of > 2 alcoholic drinks per day or use of illegal drugs within 12 months of screening
Not suitable for study participation due to other reasons at the investigators discretion
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note